Sort
48,018 grants matching “immunotherapy”
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
$363,164Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers
$363,164Faye Johnson · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers
$363,164Faye Johnson · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
$363,164Wei Gu · Columbia University Health Sciences · R01 · FY2022 · CA
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
$363,164Juan Fueyo · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
$363,164Wei Gu · Columbia University Health Sciences · R01 · FY2023 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
$363,164Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Toward understanding the role of altered glycosylation in cancer
$363,139Stacy Alyse Malaker · Yale University · R35 · FY2022 · GM
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
$363,125Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2011 · CA
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
$363,125Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2015 · CA
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
$363,125Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2012 · CA
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
$363,090Andrew E Aplin · Thomas Jefferson University · R01 · FY2022 · CA
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma
$363,090Roger S Lo · University Of California Los Angeles · R01 · FY2023 · CA
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma
$363,090Roger S Lo · University Of California Los Angeles · R01 · FY2022 · CA
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2
$363,077Dai Fukumura · Massachusetts General Hospital · R01 · FY2025 · NS
Mechanisms of epigenetic memory in human cells
$363,057James Karlo Nunez · University Of California Berkeley · R35 · FY2024 · GM
CD8+ T Cell-Mediated Immunotherapy of Autochthonous SV40 T Antigen-Induced Tumors
$363,051Todd D Schell · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2014 · CA
P5 - P-53-Based Vaccine for Small Cell Lung Cancer
$363,048Dmitry Isaac Gabrilovich · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2010 · CA
Autoimmune vitiligo and tolerance in the immune response to a melanoma antigen
$363,046Victor H. Engelhard · University Of Virginia · R01 · FY2011 · AI
A Critical Role for the Microvasculature in Airway Transplantation
$363,037Mark Robert Nicolls · Palo Alto Veterans Instit For Research · R01 · FY2011 · HL
Core 2
$362,923Kavita Dhodapkar · Emory University · P01 · FY2024 · CA
Development of promoters of dendritic spine formation
$362,895Jerry Yang · University Of California, San Diego · R01 · FY2016 · AG
STING-dependent activation of Natural Killer cells by viral and tumor DNA
$362,894David H Raulet · University Of California Berkeley · R01 · FY2020 · AI
Targeting oncogenic epigenetic mechanisms in IDHmut/ATRXloss Astrocytoma
$362,823Yunqing Li · Hugo W. Moser Res Inst Kennedy Krieger · R01 · FY2024 · NS
Ubiquitinated Proteins in Exosomes of Immune Suppressive Myeloid Cells
$362,818Catherine C. Fenselau · Univ Of Maryland, College Park · R01 · FY2017 · GM